291650 — Aptamer Sciences Income Statement
0.000.00%
Last trade - 00:00
- KR₩46bn
- KR₩31bn
- KR₩243m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 408 | 229 | 269 | 358 | 243 |
Cost of Revenue | |||||
Gross Profit | -802 | -974 | -1,080 | -1,222 | -1,620 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,699 | 4,151 | 4,336 | 8,678 | 12,450 |
Operating Profit | -3,292 | -3,923 | -4,067 | -8,320 | -12,207 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3,853 | -3,843 | -3,831 | -8,301 | -13,602 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3,853 | -3,843 | -3,831 | -7,116 | -13,602 |
Net Income Before Extraordinary Items | |||||
Net Income | -3,853 | -3,843 | -3,831 | -7,116 | -13,602 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -3,853 | -3,843 | -3,831 | -7,116 | -13,602 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -382 | -256 | -227 | -419 | -801 |
Dividends per Share |